Important points for the standard treatment of resectable pancreatic cancer-Reference-Cited by-同舟云学术

Important points for the standard treatment of resectable pancreatic cancer

Published:2021-02-28 Issue:1 Volume:36 Page:57-63
ISSN:0913-0071
Container-title:Suizo
language:en
Short-container-title:Journal of the Japan Pancreas Society

Author:

YAMAMINE Naoki¹,SHIBUYA Kazuto¹,YOSHIOKA Isaku¹,HIRANO Katsuhisa¹,WATANABE Toru¹,HOSHINO Yui¹,MORI Kosuke¹,KIMURA Nana¹,ITO Ayaka¹,BABA Hayato¹,MIWA Takeshi¹,HOJO Shozo¹,MATSUI Koshi¹,OKUMURA Tomoyuki¹,FUJII Tsutomu¹

Affiliation:

1. Department of Surgery and Science Faculty of Medicine, Academic Assembly University of Toyama

Publisher

Japan Pancreas Society

Link

https://www.jstage.jst.go.jp/article/suizo/36/1/36_57/_pdf

Reference23 articles.

1. 1) Motoi F, Kosuge T, Ueno H, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol 2019; 49: 190-4.

2. 3) Nawaz H, Fan CY, Kloke J, et al. Performance characteristics of endoscopic ultrasound in the staging of pancreatic cancer: a meta-analysis. JOP 2013; 14: 484-97.

3. 4) Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013; 310: 1473-81.

4. 5) Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 2016; 388: 248-57.

5. 7) Tanaka M, Mihaljevic AL, Probst P, et al. Meta-analysis of recurrence pattern after resection for pancreatic cancer. Br J Surg 2019; 106: 1590-601.